Search results
Hace 4 días · Pictured: Gilead corporate headquarters in Silicon Valley iStock/Sundry Photography Gilead Sciences announced Saturday that Seladelpar, part of the $4.3 billion purchase of CymaBay in February 2024, posted positive interim late-stage results in patients with the autoimmune disease primary biliary cholangitis.. The Phase III ASSURE study is investigating the once-daily selective peroxisome ...
Hace 6 días · - 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months - - Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Patients with Moderate to Severe Symptoms - - Positive Interim Results are Highly Consistent with Results from the Phase 3 RESPONSE Study of Seladelpar - Gilead Sciences ...
Hace 15 horas · Gilead Sciences is bolstering its liver disease portfolio with the $4.3 billion acquisition of CymaBay Therapeutics, specifically for the primary biliary cholangitis (PBC) med seladelpar. The deal follows a Big Pharma trend of picking up late-stage, validated assets. Seladelpar was submitted to the FDA to treat PBC with pruritus, or itching, without cirrhosis or with…
Hace 4 días · Interim results from the open-label Phase 3 ASSURE study showed that the drug improved biomarkers in primary biliary cholangitis, a rare chronic autoimmune disease that mostly affects women and eventually destroys the body’s bile ducts, with fatigue and itching as early signs.
Hace 4 días · Gilead's new liver disease med continues to deliver the goods ahead of FDA verdict. Three months after spending $4.3 billion on CymaBay Therapeutics for its primary biliary cholangitis (PBC) med ...
26 de abr. de 2024 · After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on Trodelvy, which serves as the cornerstone of the company’s solid tumor ambition.
Hace 4 días · News Reporter. Gilead reported more positive data over the weekend from its rare liver disease drug candidate seladelpar, which it got when it snapped up CymaBay for $4.3 ...
